CytoDyn Announces Cancer Update: 12-month Analysis of 28 mTNBC Patients Receiving Leronlimab Suggests an Increase of 3600% in 12-month OS in 75% of Patients with a Lower Level of Circulating Cells After Leronlimab Induction or at Baseline; 12-month PFS Continues at Near 600% Increase
03 nov. 2021 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Nov. 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA
28 oct. 2021 00h41 HE
|
CytoDyn Inc.
Management expects the non-clinical and CMC sections of the BLA to be resubmitted to FDA in November VANCOUVER, Washington, Oct. 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn"...
CytoDyn Announces Treatment of First Patient in Pivotal Phase 3 Trial for Critically Ill COVID-19 Patients in Brazil
25 oct. 2021 06h00 HE
|
CytoDyn Inc.
Based on previous strong sub-population analysis in CD12 trial, CytoDyn intends to file for an EUA when interim analysis of 127 patients is completed VANCOUVER, Washington, Oct. 25, 2021 (GLOBE...
CytoDyn to Hold Webcast and Live Q/A on October 26
21 oct. 2021 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Oct. 21, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn to Present at Emerging Growth Conference on October 13 Followed by Live Q/A
07 oct. 2021 14h27 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint Blockade (ICB)
07 oct. 2021 06h02 HE
|
CytoDyn Inc.
Clinical Trial Development Targeting Triple-Negative Breast Cancer (TNBC) to Evaluate Anti-Tumor Effects and Identify Immunological Biomarkers for Leronlimab in Combination with Immune Checkpoint...
CytoDyn Names Chris Recknor, M.D. Senior Executive VP of Clinical Operations to Initiate Two New Clinical Trials for Stroke and Alzheimer’s, While Nitya Ray, Ph.D. is Named CytoDyn’s New COO to Lead CMC and Regulatory Operations Specifically the BLA for HIV
07 oct. 2021 06h01 HE
|
CytoDyn Inc.
New hires in Bioanalytical Sciences, Biostatistics, Clinical Regulatory, and Clinical Project Management will join the team of Drs. Srinivasan, Recknor, Ray, and Kelly to lead all clinical trials with...
CytoDyn Announces Legal Actions Against its Former CRO, Amarex Clinical Research
07 oct. 2021 06h00 HE
|
CytoDyn Inc.
All clinical activities have been moved away from Amarex; a complete update on all activities will be provided to shareholders next week by Drs. Recknor, Kelly, Ray, and Pourhassan VANCOUVER,...
CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A
13 sept. 2021 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Sept. 13, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms
09 sept. 2021 20h30 HE
|
CytoDyn Inc.
An interim analysis will be conducted 28 days following enrollment of 245 patients (40% of targeted trial patients) VANCOUVER, Washington, Sept. 09, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:...